-
Product Insights
Pandemic Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Pandemic Influenza - Drugs In Development, 2023’, provides an overview of the Pandemic Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pandemic Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cervical Intraepithelial Neoplasia (CIN) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2023’, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Influenzavirus A Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenzavirus A Infections - Drugs In Development, 2023’, provides an overview of the Influenzavirus A Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenzavirus A Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLY-2608 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLY-2608 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLY-2608 in Cervical Cancer Drug Details: RLY-2608 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-207 in Anal Fistula
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AB-207 in Anal FistulaDrug Details:E-CEL UVEC is under development for the treatment of anal fistula, 2nd GI...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-205 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-205 in Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AB-205 in Non-Hodgkin Lymphoma Drug Details:AB-205 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VCAR-33 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VCAR-33 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tremtelectogene empogeditemcel in Refractory Acute Myeloid Leukemia Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VCAR-33 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VCAR-33 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tremtelectogene empogeditemcel in Acute Myelocytic Leukemia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-110 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-110 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AB-110 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...